Expression of B and T Lymphocyte Attenuator in Patients with Severe Community-Acquired Pneumonia and the Effect of Steroid Therapy in a Mouse Model

Zhou, Guoqing; Wang, Daoxin; Liu, Daishun; Qi, Di

doi:10.7754/clin.lab.2016.160521

Cited by 4 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The lymphoid stem cells that differentiate from pluripotent stem cells can migrate in the blood, move to the thymus gland and mature within the thymus; therefore, these cells are termed thymus-dependent lymphocytes or T lymphocytes. Bone marrow cells that mature in the bone marrow are known as bone marrow-dependent lymphocytes, which are B lymphocytes (32). T and B lymphocytes stimulated by an antigen or mitogen in vitro can be converted into larger, metabolically competent, mitotic lymphoblasts (33).…”

Section: Discussionmentioning

confidence: 99%

Immune promotive effect of bioactive peptides may be mediated by regulating the expression of SOCS1/miR‑155

Chen

2019

Exp Ther Med

View full text Add to dashboard Cite

The present study was designed to evaluate the effect of bioactive hepatic peptide (BHP) on the immune function of mice and to examine the mechanism mediated by the related factors cytokine suppressor of cytokine signaling 1 (SOCS1) and microRNA (miR)-155. The mice were divided into eight groups, including a normal mouse group, normal peptide groups (low-dose, mid-dose and high-dose), an immunosuppressed group, and immunosuppressed with peptide groups (low-dose, mid-dose and high-dose). The proliferative ability of splenic lymphocytes was determined in vitro using a Cell Counting kit-8 assay. Wright's staining was used to assess the phagocytic function of macrophages. Histological changes in the spleen were evaluated by hematoxylin-eosin staining. The relevant factors SOCS1/miR-155 were assessed by immunohistochemistry and reverse transcription fluorescence-quantitative polymerase chain reaction analysis. The levels of the cytokines TGF-β1, IL-10 and IL-17A were determined by enzyme-linked immunosorbent assay. First, the organ index, percentage of lymphocytes, phagocytosis experiments and splenic lymphocyte proliferation test results revealed that the immunodeficient mouse model had been successfully established. Second, compared with the control mice, the normal peptide group mice exhibited increased spleen and thymus indices, percentages of lymphocyte subsets, macrophage phagocytosis percentages, phagocytic indices, splenic lymphocyte proliferation and expression of miR-155; however, the expression of SOCS1 was decreased in the normal peptide groups to varying extents. In addition, the expression of SOCS1 was upregulated, whereas that of miR-155 was downregulated in the immunosuppressed group. Compared with the mice in the immunosuppressed group, the mice in the immunosuppressed with peptide groups had increased spleen and thymus indices, percentages of lymphocyte subsets, macrophage phagocytosis percentages, phagocytic indices, splenic lymphocyte proliferation and expression of miR-155; however, the expression of SOCS1 was decreased in the immunosuppressed with peptide groups to varying extents. Following treatment with BHP, the secretion of TGF-β1 in the spleen of the normal mice and immunosuppressed mice was significantly decreased, and the secretion of IL-10 was significantly increased. No significant difference in the expression of IL-17A was observed among the groups. In summary, BHP improved the immune function of the normal mice and immunosuppressed mice. This data provides a scientific basis for the development of bioactive peptide health products.

show abstract

Section: Discussionmentioning

confidence: 99%

Immune promotive effect of bioactive peptides may be mediated by regulating the expression of SOCS1/miR‑155

Chen

2019

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…In patients with chronic HBV infection, a subset of antigen-specific CD8 + T cells with low IFN-γ production express high levels of BTLA, and these cells play a vital role in the regulation of CD8 + T cell responses via BTLA signaling ( 94 ). In patients with severe community-acquired pneumonia and in mice with acute lung inflammation, circulating BTLA + CD4 + lymphocyte proportions markedly increased, whereas agonistic anti-BTLA antibody reduced the activation of the NF-κB pathway and attenuated the inflammatory responses ( 95 ). In mice infected with the parasitic nematode Strongyloides ratti , BTLA expression in CD4 + T cells was upregulated.…”

Section: The Functions Of Btla In Immune-related Diseasesmentioning

confidence: 99%

“…Studies have examined the role of anti-BTLA antibodies in tumor, inflammatory diseases, and transplantation rejection. The findings show that BTLA-neutralizing antibodies can inhibit tumor development ( 50 ), while agonistic anti-BTLA antibody treatment reduces inflammation ( 63 , 95 ) and prolongs allograft survival ( 108 , 110 , 111 ). However, these antibodies may not always act exactly as predicted, since different BTLA antibodies may have opposite functions.…”

Section: Perspectivesmentioning

confidence: 99%

Roles of BTLA in Immunity and Immune Disorders

2021

View full text Add to dashboard Cite

B and T lymphocyte attenuator (BTLA) is one of the most important cosignaling molecules. It belongs to the CD28 superfamily and is similar to programmed cell death-1 (PD-1) and cytotoxic T lymphocyte associated antigen-4 (CTLA-4) in terms of its structure and function. BTLA can be detected in most lymphocytes and induces immunosuppression by inhibiting B and T cell activation and proliferation. The BTLA ligand, herpesvirus entry mediator (HVEM), does not belong to the classic B7 family. Instead, it is a member of the tumor necrosis factor receptor (TNFR) superfamily. The association of BTLA with HVEM directly bridges the CD28 and TNFR families and mediates broad and powerful immune effects. Recently, a large number of studies have found that BTLA participates in numerous physiopathological processes, such as tumor, inflammatory diseases, autoimmune diseases, infectious diseases, and transplantation rejection. Therefore, the present work aimed to review the existing knowledge about BTLA in immunity and summarize the diverse functions of BTLA in various immune disorders.

show abstract

“…Increasing BTLA expression via either the administration of dexamethasone or the agonistic anti-BTLA antibody 6A6 attenuates LPS-induced acute lung inflammation in mice (Table 4) (45). BTLA may be involved in regulating the immune response in patients with severe CAP, affecting the outcome of this disease.…”

Section: Btla In Pneumonia and Acute Respiratory Distress Syndromementioning

confidence: 99%

The Role of B and T Lymphocyte Attenuator in Respiratory System Diseases

et al. 2021

View full text Add to dashboard Cite

B and T lymphocyte attenuator (BTLA), an immunomodulatory molecule widely expressed on the surface of immune cells, can influence various signaling pathways and negatively regulate the activation and proliferation of immune cells by binding to its ligand herpes virus entry mediator (HVEM). BTLA plays an important role in immunoregulation and is involved in the pathogenesis of various respiratory diseases, including airway inflammation, asthma, infection, pneumonia, acute respiratory distress syndrome and lung cancer. In recent years, some studies have found that BTLA also has played a positive regulatory effect on immunity system in the occurrence and development of respiratory diseases. Since severe pulmonary infection is a risk factor for sepsis, this review also summarized the new findings on the role of BTLA in sepsis.

show abstract

Expression of B and T Lymphocyte Attenuator in Patients with Severe Community-Acquired Pneumonia and the Effect of Steroid Therapy in a Mouse Model

Abstract: These results demonstrated that BTLA may be a therapeutic target for the treatment of severe CAP and that BTLA expression may reflect the body's immune status and guide decisions regarding steroid therapy for treating severe CAP.

Cited by 4 publications

References 0 publications

Immune promotive effect of bioactive peptides may be mediated by regulating the expression of SOCS1/miR‑155

Immune promotive effect of bioactive peptides may be mediated by regulating the expression of SOCS1/miR‑155

Roles of BTLA in Immunity and Immune Disorders

The Role of B and T Lymphocyte Attenuator in Respiratory System Diseases

Contact Info

Product

Resources

About